SkunkWorx Bio was recently awarded an STTR grant from the NIH
SkunkWorx Bio was recently awarded an STTR grant from the NIH to work on pediatric ATRT tumors in collaboration with Weill Cornell Medical Center. These tumors are highly lethal and there are few available treatment options available. Patients have poor survival outcomes. SkunkWorx believes that its bispecific drug conjugate, 429-SM, is a first-in-class therapeutic and […]
SkunkWorx Bio was recently awarded an STTR grant from the NIH Read More »
